Different mechanisms for resistance to trastuzumab versus lapatinib in HER2- positive breast cancers - role of estrogen receptor and HER2 reactivation
Yen-Chao Wang(Baylor College of Medicine), Rachel Schiff(Baylor College of Medicine)
Cited by 283
Related Papers
Crosstalk between the Estrogen Receptor and the HER Tyrosine Kinase Receptor Family: Molecular Mechanism and Clinical Implications for Endocrine Therapy Resistance
|Endocrine Reviews|2008|545
Treatment of Human Epidermal Growth Factor Receptor 2-Overexpressing Breast Cancer Xenografts With Multiagent HER-Targeted Therapy
|JNCI Journal of the National Cancer Institute|2007|189
β1 integrin mediates an alternative survival pathway in breast cancer cells resistant to lapatinib
|Breast Cancer Research|2011|162